Click here to get full coverage on Why Is the Market Watching Silexion Therapeutics (SLXN)? - Kalkine Media

Why Is the Market Watching Silexion Therapeutics (SLXN)?  Kalkine Media

Why Is the Market Watching Silexion Therapeutics (SLXN)? - Kalkine Media

Click here to get full coverage on Most active stocks in Thursday's session - ChartMill

Most active stocks in Thursday's session  ChartMill

Most active stocks in Thursday's session - ChartMill

Click here to get full coverage on Silexion Therapeutics to Participate in September 2026 Industry and Investor Conferences - GlobeNewswire

Silexion Therapeutics to Participate in September 2026 Industry and Investor Conferences  GlobeNewswire

Silexion Therapeutics to Participate in September 2026 Industry and Investor Conferences - GlobeNewswire

Click here to get full coverage on Silexion Therapeutics (SLXN) spikes as investors react to mid-May clinical-trial milestones and fresh financing - Quiver Quantitative

Silexion Therapeutics (SLXN) spikes as investors react to mid-May clinical-trial milestones and fresh financing  Quiver Quantitative

Silexion Therapeutics (SLXN) spikes as investors react to mid-May clinical-trial milestones and fresh financing - Quiver Quantitative

Click here to get full coverage on SLXN Forecast — Price Target — Prediction for 2027 - TradingView

SLXN Forecast — Price Target — Prediction for 2027  TradingView

SLXN Forecast — Price Target — Prediction for 2027 - TradingView

Click here to get full coverage on (SLXN) and the Role of Price-Sensitive Allocations - Stock Traders Daily

(SLXN) and the Role of Price-Sensitive Allocations  Stock Traders Daily

(SLXN) and the Role of Price-Sensitive Allocations - Stock Traders Daily

Click here to get full coverage on Silexion Therapeutics is developing a potential “holy grail” play in precision oncology (NASDAQ: SLXN) By FinanceWire - Investing.com

Silexion Therapeutics is developing a potential “holy grail” play in precision oncology (NASDAQ: SLXN) By FinanceWire  Investing.com

Silexion Therapeutics is developing a potential “holy grail” play in precision oncology (NASDAQ: SLXN) By FinanceWire - Investing.com

Click here to get full coverage on Most Active US Stocks on Sept. 10, 2026 - ChartMill

Most Active US Stocks on Sept. 10, 2026  ChartMill

Most Active US Stocks on Sept. 10, 2026 - ChartMill

Click here to get full coverage on Biotech Pre-Market Pulse: DRMA, DFTX Jump While SLXN Tumbles - RTTNews

Biotech Pre-Market Pulse: DRMA, DFTX Jump While SLXN Tumbles  RTTNews

Biotech Pre-Market Pulse: DRMA, DFTX Jump While SLXN Tumbles - RTTNews

Click here to get full coverage on Silexion Therapeutics Announces Pricing of $2.5 Million Public Offering - Yahoo Finance

Silexion Therapeutics Announces Pricing of $2.5 Million Public Offering  Yahoo Finance

Silexion Therapeutics Announces Pricing of $2.5 Million Public Offering - Yahoo Finance

Click here to get full coverage on Silexion Therapeutics Announces 1-for-10 Reverse Share Split - GlobeNewswire

Silexion Therapeutics Announces 1-for-10 Reverse Share Split  GlobeNewswire

Silexion Therapeutics Announces 1-for-10 Reverse Share Split - GlobeNewswire

Click here to get full coverage on Premarket movers Sept. 10, 2026: TNONW, TNON among gainers; CDT, MGN among losers - ChartMill

Premarket movers Sept. 10, 2026: TNONW, TNON among gainers; CDT, MGN among losers  ChartMill

Premarket movers Sept. 10, 2026: TNONW, TNON among gainers; CDT, MGN among losers - ChartMill

Click here to get full coverage on Silexion Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update - GlobeNewswire

Silexion Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update  GlobeNewswire

Silexion Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update - GlobeNewswire

Click here to get full coverage on Silexion Therapeutics Reports New Positive Preclinical Findings Demonstrating Multi-Mechanism Immune Sensitization by SIL204 in KRAS-Driven Cancers - GlobeNewswire

Silexion Therapeutics Reports New Positive Preclinical Findings Demonstrating Multi-Mechanism Immune Sensitization by SIL204 in KRAS-Driven Cancers  GlobeNewswire

Silexion Therapeutics Reports New Positive Preclinical Findings Demonstrating Multi-Mechanism Immune Sensitization by SIL204 in KRAS-Driven Cancers - GlobeNewswire

Click here to get full coverage on Silexion Therapeutics Announces Successful Submission of Phase 2/3 Clinical Trial Application to Germany’s BfArM for SIL204 in KRAS-Driven Locally Advanced Pancreatic Cancer - GlobeNewswire

Silexion Therapeutics Announces Successful Submission of Phase 2/3 Clinical Trial Application to Germany’s BfArM for SIL204 in KRAS-Driven Locally Advanced Pancreatic Cancer  GlobeNewswire

Silexion Therapeutics Announces Successful Submission of Phase 2/3 Clinical Trial Application to Germany’s BfArM for SIL204 in KRAS-Driven Locally Advanced Pancreatic Cancer - GlobeNewswire

Click here to get full coverage on Traders are paying attention to the gapping stocks in Wednesday's session. - ChartMill

Traders are paying attention to the gapping stocks in Wednesday's session.  ChartMill

Traders are paying attention to the gapping stocks in Wednesday's session. - ChartMill

Click here to get full coverage on Silexion Therapeutics Receives Approval from Germany's BfArM to Initiate Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer - GlobeNewswire

Silexion Therapeutics Receives Approval from Germany's BfArM to Initiate Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer  GlobeNewswire

Silexion Therapeutics Receives Approval from Germany's BfArM to Initiate Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer - GlobeNewswire

Click here to get full coverage on Stay updated with the stocks that are on the move in today's pre-market session. - ChartMill

Stay updated with the stocks that are on the move in today's pre-market session.  ChartMill

Stay updated with the stocks that are on the move in today's pre-market session. - ChartMill

Click here to get full coverage on Silexion Therapeutics Announces Exercise of Warrants for $1 Million Gross Proceeds - GlobeNewswire

Silexion Therapeutics Announces Exercise of Warrants for $1 Million Gross Proceeds  GlobeNewswire

Silexion Therapeutics Announces Exercise of Warrants for $1 Million Gross Proceeds - GlobeNewswire

Click here to get full coverage on Silexion Reports $3.6 Million Second-Quarter Net Loss as SIL204 Trial Starts | SLXNW Stock News - Quiver Quantitative

Silexion Reports $3.6 Million Second-Quarter Net Loss as SIL204 Trial Starts | SLXNW Stock News  Quiver Quantitative

Silexion Reports $3.6 Million Second-Quarter Net Loss as SIL204 Trial Starts | SLXNW Stock News - Quiver Quantitative

Click here to get full coverage on Silexion Therapeutics Successfully Initiates Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer at Tel Aviv Sourasky Medical Center - GlobeNewswire

Silexion Therapeutics Successfully Initiates Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer at Tel Aviv Sourasky Medical Center  GlobeNewswire

Silexion Therapeutics Successfully Initiates Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer at Tel Aviv Sourasky Medical Center - GlobeNewswire

Click here to get full coverage on Silexion Therapeutics Company Profile & Introduction - moomoo.com

Silexion Therapeutics Company Profile & Introduction  moomoo.com

Silexion Therapeutics Company Profile & Introduction - moomoo.com

Click here to get full coverage on Silexion Therapeutics Announces Initiation of GMP Clinical Supply Manufacturing of SIL204 with Leading Global CDMO, and New Approval of Phase 2/3 Trial From Tel Aviv Sourasky Medical Center - GlobeNewswire

Silexion Therapeutics Announces Initiation of GMP Clinical Supply Manufacturing of SIL204 with Leading Global CDMO, and New Approval of Phase 2/3 Trial From Tel Aviv Sourasky Medical Center  GlobeNewswire

Silexion Therapeutics Announces Initiation of GMP Clinical Supply Manufacturing of SIL204 with Leading Global CDMO, and New Approval of Phase 2/3 Trial From Tel Aviv Sourasky Medical Center - GlobeNewswire

Click here to get full coverage on symbol__ Stock Quote Price and Forecast - CNN

symbol__ Stock Quote Price and Forecast  CNN

symbol__ Stock Quote Price and Forecast - CNN

Click here to get full coverage on Silexion stock falls after receiving German regulatory feedback - Investing.com

Silexion stock falls after receiving German regulatory feedback  Investing.com

Silexion stock falls after receiving German regulatory feedback - Investing.com

Click here to get full coverage on Silexion Therapeutics Receives Approval from Israeli Ministry of Health to Initiate Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer - GlobeNewswire

Silexion Therapeutics Receives Approval from Israeli Ministry of Health to Initiate Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer  GlobeNewswire

Silexion Therapeutics Receives Approval from Israeli Ministry of Health to Initiate Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer - GlobeNewswire

Click here to get full coverage on Silexion Therapeutics to Attend 7th Annual RNAi-Based Therapeutics Summit - GlobeNewswire

Silexion Therapeutics to Attend 7th Annual RNAi-Based Therapeutics Summit  GlobeNewswire

Silexion Therapeutics to Attend 7th Annual RNAi-Based Therapeutics Summit - GlobeNewswire

Click here to get full coverage on SLXN Q1 2026 Earnings: Narrower-Than-Expected Loss Drives EPS Beat, Stock Slips 3.57% - Investor Earnings Call - vinanet.vn

SLXN Q1 2026 Earnings: Narrower-Than-Expected Loss Drives EPS Beat, Stock Slips 3.57% - Investor Earnings Call  vinanet.vn

SLXN Q1 2026 Earnings: Narrower-Than-Expected Loss Drives EPS Beat, Stock Slips 3.57% - Investor Earnings Call - vinanet.vn

Click here to get full coverage on SLXN Q1 2026 Earnings: Narrower Loss Beats Estimates, Yet Shares Tumble 29% - Earnings Season Review - vinanet.vn

SLXN Q1 2026 Earnings: Narrower Loss Beats Estimates, Yet Shares Tumble 29% - Earnings Season Review  vinanet.vn

SLXN Q1 2026 Earnings: Narrower Loss Beats Estimates, Yet Shares Tumble 29% - Earnings Season Review - vinanet.vn

Click here to get full coverage on SLXN Q1 2026 Earnings: Narrower Loss of -8.5 Per Share Beats Consensus by 35.4% as Clinical-Stage Spending Stays in Check - Analyst Drop Coverage - vinanet.vn

SLXN Q1 2026 Earnings: Narrower Loss of -8.5 Per Share Beats Consensus by 35.4% as Clinical-Stage Spending Stays in Check - Analyst Drop Coverage  vinanet.vn

SLXN Q1 2026 Earnings: Narrower Loss of -8.5 Per Share Beats Consensus by 35.4% as Clinical-Stage Spending Stays in Check - Analyst Drop Coverage - vinanet.vn

Click here to get full coverage on SLXN Stock Price and Chart — NASDAQ:SLXN - TradingView

SLXN Stock Price and Chart — NASDAQ:SLXN  TradingView

SLXN Stock Price and Chart — NASDAQ:SLXN - TradingView

Click here to get full coverage on What is the current Price Target and Forecast for Silexion Therapeutics Corp (SLXN) - Zacks Investment Research

What is the current Price Target and Forecast for Silexion Therapeutics Corp (SLXN)  Zacks Investment Research

What is the current Price Target and Forecast for Silexion Therapeutics Corp (SLXN) - Zacks Investment Research

Click here to get full coverage on SLXN Q1 2026 Earnings: Narrower Loss Beats Estimates, Yet Shares Tumble 29% - Dividend Increase Stocks - dars.gov.et

SLXN Q1 2026 Earnings: Narrower Loss Beats Estimates, Yet Shares Tumble 29% - Dividend Increase Stocks  dars.gov.et

SLXN Q1 2026 Earnings: Narrower Loss Beats Estimates, Yet Shares Tumble 29% - Dividend Increase Stocks - dars.gov.et

Click here to get full coverage on SLXN Q1 2026 Earnings: Narrower-than-Expected Loss as Biotech Advances Pipeline - Earnings Expansion Phase - dars.gov.et

SLXN Q1 2026 Earnings: Narrower-than-Expected Loss as Biotech Advances Pipeline - Earnings Expansion Phase  dars.gov.et

SLXN Q1 2026 Earnings: Narrower-than-Expected Loss as Biotech Advances Pipeline - Earnings Expansion Phase - dars.gov.et

Click here to get full coverage on SLXN Q1 2026 Earnings: Narrower Loss Beats Estimates, but Stock Falls 31% - Balance Sheet Strength - vinanet.vn

SLXN Q1 2026 Earnings: Narrower Loss Beats Estimates, but Stock Falls 31% - Balance Sheet Strength  vinanet.vn

SLXN Q1 2026 Earnings: Narrower Loss Beats Estimates, but Stock Falls 31% - Balance Sheet Strength - vinanet.vn

Click here to get full coverage on Silexion Therapeutics (SLXN) Stock Forecast and Price Target 2026 - MarketBeat

Silexion Therapeutics (SLXN) Stock Forecast and Price Target 2026  MarketBeat

Silexion Therapeutics (SLXN) Stock Forecast and Price Target 2026 - MarketBeat

Click here to get full coverage on SLXN Q1 2026 Earnings: Narrower-than-Expected Loss as Biotech Advances Pipeline - Profit Inflection Point - dars.gov.et

SLXN Q1 2026 Earnings: Narrower-than-Expected Loss as Biotech Advances Pipeline - Profit Inflection Point  dars.gov.et

SLXN Q1 2026 Earnings: Narrower-than-Expected Loss as Biotech Advances Pipeline - Profit Inflection Point - dars.gov.et

Click here to get full coverage on SLXN Q1 2026 Earnings: Narrower-Than-Expected Loss Drives EPS Beat, Stock Slips 3.57% - Preliminary Results - dars.gov.et

SLXN Q1 2026 Earnings: Narrower-Than-Expected Loss Drives EPS Beat, Stock Slips 3.57% - Preliminary Results  dars.gov.et

SLXN Q1 2026 Earnings: Narrower-Than-Expected Loss Drives EPS Beat, Stock Slips 3.57% - Preliminary Results - dars.gov.et

Click here to get full coverage on Silexion Therapeutics (SLXN) Edges Lower Amid Biotech Sector Volatility - Golden Cross - dars.gov.et

Silexion Therapeutics (SLXN) Edges Lower Amid Biotech Sector Volatility - Golden Cross  dars.gov.et

Silexion Therapeutics (SLXN) Edges Lower Amid Biotech Sector Volatility - Golden Cross - dars.gov.et

Click here to get full coverage on Should I buy Silexion Therapeutics Corp (SLXN) - Zacks Investment Research

Should I buy Silexion Therapeutics Corp (SLXN)  Zacks Investment Research

Should I buy Silexion Therapeutics Corp (SLXN) - Zacks Investment Research

Click here to get full coverage on Silexion Therapeutics (SLXN) Stock Price, News & Analysis - MarketBeat

Silexion Therapeutics (SLXN) Stock Price, News & Analysis  MarketBeat

Silexion Therapeutics (SLXN) Stock Price, News & Analysis - MarketBeat

Click here to get full coverage on Silexion Therapeutics Corp. to Present at 27th Annual H.C. Wainwright Global Investment Conference - Quiver Quantitative

Silexion Therapeutics Corp. to Present at 27th Annual H.C. Wainwright Global Investment Conference  Quiver Quantitative

Silexion Therapeutics Corp. to Present at 27th Annual H.C. Wainwright Global Investment Conference - Quiver Quantitative

Click here to get full coverage on Silexion Stock Hits Record Intraday Low After Pricing $5M Offering, But Retail Excitement Over Cancer Data Endures - Stocktwits

Silexion Stock Hits Record Intraday Low After Pricing $5M Offering, But Retail Excitement Over Cancer Data Endures  Stocktwits

Silexion Stock Hits Record Intraday Low After Pricing $5M Offering, But Retail Excitement Over Cancer Data Endures - Stocktwits

Click here to get full coverage on Silexion Therapeutics Corp (SLXN) Stock Price, News, Quote & History - Yahoo Finance

Silexion Therapeutics Corp (SLXN) Stock Price, News, Quote & History  Yahoo Finance

Silexion Therapeutics Corp (SLXN) Stock Price, News, Quote & History - Yahoo Finance

Click here to get full coverage on TRIB, SLXN, STSS: Why Retail Chatter On 3 Nano-Cap Healthcare Stocks Exploded Over 6000% - Stocktwits

TRIB, SLXN, STSS: Why Retail Chatter On 3 Nano-Cap Healthcare Stocks Exploded Over 6000%  Stocktwits

TRIB, SLXN, STSS: Why Retail Chatter On 3 Nano-Cap Healthcare Stocks Exploded Over 6000% - Stocktwits

Click here to get full coverage on Silexion Therapeutics stock falls after warrant exercise deal - Investing.com

Silexion Therapeutics stock falls after warrant exercise deal  Investing.com

Silexion Therapeutics stock falls after warrant exercise deal - Investing.com

Click here to get full coverage on SLXN Forecast — Price Prediction for 2026. Should I Buy SLXN? - Intellectia AI

SLXN Forecast — Price Prediction for 2026. Should I Buy SLXN?  Intellectia AI

SLXN Forecast — Price Prediction for 2026. Should I Buy SLXN? - Intellectia AI

Click here to get full coverage on Technical Analysis of Silexion Therapeutics Corp (NASDAQ:SLXN) - TradingView

Technical Analysis of Silexion Therapeutics Corp (NASDAQ:SLXN)  TradingView

Technical Analysis of Silexion Therapeutics Corp (NASDAQ:SLXN) - TradingView

Click here to get full coverage on Silexion Therapeutics Corp (SLXN) analyst ratings, estimates and forecasts - Yahoo Finance Australia

Silexion Therapeutics Corp (SLXN) analyst ratings, estimates and forecasts  Yahoo Finance Australia

Silexion Therapeutics Corp (SLXN) analyst ratings, estimates and forecasts - Yahoo Finance Australia

Click here to get full coverage on Silexion Therapeutics Ltd. and Moringa Acquisition Corp Announce Closing of their Business Combination - Yahoo Finance

Silexion Therapeutics Ltd. and Moringa Acquisition Corp Announce Closing of their Business Combination  Yahoo Finance

Silexion Therapeutics Ltd. and Moringa Acquisition Corp Announce Closing of their Business Combination - Yahoo Finance

Click here to get full coverage on Silexion Therapeutics Ltd (SLXN) sentiment score, message volume, participation score and buzz level - Stocktwits

Silexion Therapeutics Ltd (SLXN) sentiment score, message volume, participation score and buzz level  Stocktwits

Silexion Therapeutics Ltd (SLXN) sentiment score, message volume, participation score and buzz level - Stocktwits

Click here to get full coverage on Diluted shares outstanding of Silexion Therapeutics Corp – NASDAQ:SLXN - TradingView

Diluted shares outstanding of Silexion Therapeutics Corp – NASDAQ:SLXN  TradingView

Diluted shares outstanding of Silexion Therapeutics Corp – NASDAQ:SLXN - TradingView

Click here to get full coverage on Silexion Therapeutics To Carry Out 1-for-15 Reverse Stock Split On July 29th, 2025 - moomoo.com

Silexion Therapeutics To Carry Out 1-for-15 Reverse Stock Split On July 29th, 2025  moomoo.com

Silexion Therapeutics To Carry Out 1-for-15 Reverse Stock Split On July 29th, 2025 - moomoo.com

Click here to get full coverage on SLXN Stock Soars on Tumor Drug Promise - timothysykes.com

SLXN Stock Soars on Tumor Drug Promise  timothysykes.com

SLXN Stock Soars on Tumor Drug Promise - timothysykes.com

Click here to get full coverage on Silexion Therapeutics Corp Dividends – NASDAQ:SLXN - TradingView

Silexion Therapeutics Corp Dividends – NASDAQ:SLXN  TradingView

Silexion Therapeutics Corp Dividends – NASDAQ:SLXN - TradingView

Click here to get full coverage on Retail Traders Flocked To These 5 Biotech Stocks In January — Here’s Why - Stocktwits

Retail Traders Flocked To These 5 Biotech Stocks In January — Here’s Why  Stocktwits

Retail Traders Flocked To These 5 Biotech Stocks In January — Here’s Why - Stocktwits

Click here to get full coverage on SLXN Shares Plummet: Time to Reassess or a Buying Opportunity? - timothysykes.com

SLXN Shares Plummet: Time to Reassess or a Buying Opportunity?  timothysykes.com

SLXN Shares Plummet: Time to Reassess or a Buying Opportunity? - timothysykes.com

Click here to get full coverage on Reconstruction of Silexion’s Fortune: Bubble or Growth? - timothysykes.com

Reconstruction of Silexion’s Fortune: Bubble or Growth?  timothysykes.com

Reconstruction of Silexion’s Fortune: Bubble or Growth? - timothysykes.com

Click here to get full coverage on Silexion Therapeutics Corp (SLXN) Company Profile & Facts - Yahoo Finance

Silexion Therapeutics Corp (SLXN) Company Profile & Facts  Yahoo Finance

Silexion Therapeutics Corp (SLXN) Company Profile & Facts - Yahoo Finance

Click here to get full coverage on Silexion Therapeutics Unveils Promising SIL204 Data - TipRanks

Silexion Therapeutics Unveils Promising SIL204 Data  TipRanks

SLXN

Price Chart

Key Statistics

Technicals

About SLXN

Latest News

Why Is the Market Watching Silexion Therapeutics (SLXN)? - Kalkine Media

Most active stocks in Thursday's session - ChartMill

Silexion Therapeutics to Participate in September 2026 Industry and Investor Conferences - GlobeNewswire

Advanced Charts

Top Gainers

Top Losers